Ubs Group Ag Evaxion Biotech A/S Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.6 - $1.17 $2,236 - $4,361	-3,728 Reduced 93.08%	277 $0
Q3 2023 Nov 09, 2023	BUY	$0.48 - $1.33 $1,815 - $5,031	3,783 Added 1704.05%	4,005 $3,000
Q2 2023 Aug 11, 2023	SELL	$1.12 - $1.74 $7,120 - $11,062	-6,358 Reduced 96.63%	222 $0
Q1 2023 May 12, 2023	BUY	$1.03 - $1.8 $1,543 - $2,698	1,499 Added 29.5%	6,580 $7,000
Q4 2022 Feb 08, 2023	BUY	$1.7 - $30.2 $4,137 - $73,506	2,434 Added 91.95%	5,081 $8,000
Q3 2022 Nov 10, 2022	BUY	$1.9 - $27.7 $2,935 - $42,796	1,545 Added 140.2%	2,647 $7,000
Q2 2022 Aug 10, 2022	SELL	$1.6 - $3.07 $1,364 - $2,618	-853 Reduced 43.63%	1,102 $2,000
Q1 2022 May 16, 2022	SELL	$2.66 - $4.65 $4,168 - $7,286	-1,567 Reduced 44.49%	1,955 $6,000
Q4 2021 Feb 14, 2022	BUY	$4.0 - $12.68 $5,044 - $15,989	1,261 Added 55.77%	3,522 $16,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $9.65 $2,622 - $4,757	493 Added 27.88%	2,261 $22,000
Q2 2021 Aug 13, 2021	BUY	$5.2 - $7.94 $9,193 - $14,037	1,768 New	1,768 $14,000

37.5K

Ticker EVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,977,900
Market Cap $71.2M
Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.